Medical Cannabis A Potential Money
Studies have shown that CBD may reduce the inflammation caused by MS and may even prevent long-term nerve damage. A CBD-based treatment could potentially be combined with current medications and physical therapy to help provide sufferers of the disease with a well-rounded treatment approach. GW Pharmaceuticals created Sativex as an oral spray to provide a quick and easy application for patients dealing with muscle spasticity. The drug needs to clear Phase 3 of testing before the pharmaceutical company can submit the drug for approval in the United States, which means, as you may have guessed, more testing.
- The following CBD trials are the most up to date known to ClinicalTrials.gov.
- If further studies confirm these findings, CBD may become be a vital tool for the estimated 22 million people who deal with this distressing and life-altering issue.
- If you would like to showcase a clinical study on this page, contact our team.
- Promising CBD medical discoveries point to the possibility that it might be useful for a wide range of conditions throughout life.
It is currently illegal to market CBD by labeling it as a dietary supplement. However, this presents a problem as some CBD products are being marketed to consumers with unproven claims and with their quality and potency virtually unknown. The FDA needs much more research and information before it can begin to monitor and regulate CBD on the market effectively.
No long-term clinical trial has studied the effects of CBD and any potential side effects. It will be quite some time before a multi-decade, longitudinal CBD CBD oil clinical study is completed. In fact, a major breakthrough came in 2018 when the FDA approved a drug consisting of CBD to treat epilepsy in extreme circumstances.
Although many of these people have to resort to over-the-counter and prescription medication, research suggests CBD could be a valuable tool in relieving these symptoms. The study in question found that rats and mice that were given CBD had substantially reduced chronic pain as well as inflammation. With more comprehensive findings, CBD could eventually become a more widespread treatment thanks to its non-psychoactive compounds. Inclusion criteria included pediatric patients between the ages of 1 to 10 years with epileptic encephalopathy resistant to standard medical treatment and at minimum one major seizure per week or four major seizures per month .
Find Clinical Trials For Cannabidiol
That means doctors can now prescribe the drug when a patient suffers from Dravet syndrome, which is a rare condition that entails fever-related seizures. The medication can also work for people with Lennox-Gastaut syndrome, which tends to appear when people are between the ages of three and five and involves an array of different types of seizures.
When CBD was applied topically to the painful site, it helped reduced the amount of pain the patients felt as well as the ice/cold feelings also associated with the disease. Additionally, no adverse effects were reported in this particular study. On the other hand, a double-blind, placebo-controlled study reduces the risk of bias. In this type of study, neither the patient nor their physician knows whether the treatment the patient receives is a placebo or CBD. By moving towards double-blind, placebo-controlled trials, CBD research will begin to get more respect from the medical community.
Summing It All Up: Cbd Research
Seven participants from Saskatoon who met the inclusion criteria completed the study. All study data were collected and managed using the REDCap electronic data capture tool hosted at the University of Saskatchewan . Alphagreen and its materials are not intended to treat, diagnose, cure or prevent any disease.
Promising studies may actually begin to invoke real change in pharmacological treatment strategies. During its review of Epidiolex, the FDA identified the risk for potential liver injury. This risk can be managed when the drug is taken under medical supervision, but it isn’t clear how it may be managed when CBD is used without medical supervision. Liver injury was also shown in a 2019 study performed on rodents, but only in significant doses. Currently, the FDA has only approved one CBD product, a prescription drug designed to treat two rare forms of epilepsy.
Another study conducted in December of 2019 also studied the effect of topical CBD on pain management, and in particular, peripheral nerve damage. Peripheral nerve damage is caused by damage to nerves that causes them to send signals to the brain that is interpreted as pain.
